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Abstract
Background: Endotoxemia is commonly reported in patients receiving haemodialysis and implicated in the
pathogenesis of systemic inflammation. The Limulus Amoebocyte Lysate (LAL) assay is the most commonly used
blood endotoxin detection assay. Two kinetic variations of the assay are commercially available – the turbidimetric and
chromogenic assay, it is unknown which assay is superior for endotoxin detection in uremic patients. Selection of the
optimum LAL technique for endotoxin detection in haemodialysis patients is important to further understanding of
the sequela of endotoxemia and development of endotoxin-lowering strategies in this population.
Method: A turbidimetric and chromogenic LAL assay from the same manufacturer were directly compared. We
investigated the ability of both LAL assays to detect endotoxin in uremic plasma. Plasma samples from haemodialysis
patients and healthy controls were spiked with endotoxin and percentage spike recovery for the chromogenic and
turbidimetric assay was determined. Assay accuracy and precision were compared between both LAL assays.
Results: The turbidimetric assay had greater accuracy than the chromogenic assay. Spike recovery was 113.8 % vs. 53.
8 % for the turbidimetric and chromogenic assay respectively. Assay bias was higher in the chromogenic assay (−0.
384EU/mL vs. 0.011EU/mL). The turbidimetric assay demonstrated greater precision compared to the chromogenic assay.
Coefficient of variation ranged from 4.5 to 24.1 % for the turbidimetric assay and 25.8–26.5 % for the chromogenic assay.
Conclusion: The study findings suggest that the kinetic turbidimetric LAL assay has greater accuracy and precision than
the chromogenic assay and is the optimum LAL technique for endotoxin detection in haemodialysis patients, though
these findings should be verified using LAL reagents from other sources.
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Background
Endotoxemia is widely reported phenomenon in haemo-
dialysis (HD) patients [1, 2], however endotoxin detec-
tion in blood is difficult and the optimal assay for use in
HD patients is unknown. Many different endotoxin de-
tection assays have been employed in previous studies in
dialysis patients, including the turbidimetric Limulus
Amoebocyte Lysate (LAL) assay, chromogenic LAL
assay, Endotoxin Scattering Photometry (ESP) and Endo-
toxin Activity Assay (EAA) [2]. It is important to deter-
mine the optimum detection assay for use in patients
with end-stage kidney disease (ESKD) since endotoxemia
is reported to be associated with chronic inflammation
[3] – itself a poor prognostic marker [4]. Accurate endo-
toxin measurements are essential to further understand-
ing of the sequela of endotoxemia in this population and
to facilitate the development of potential endotoxin-
lowering strategies.
The LAL assay is the most commonly used endotoxin
detection assay. LAL is derived from extracts of primi-
tive amoebocytes present in the haemolymph of the
horseshoe crab. The lipid A component of endotoxin
interacts with pro-clotting enzymes present in LAL ac-
tivating a coagulation cascade resulting in gelation and
eventual clot formation [5]. High endotoxin content
samples lead to rapid gelation. The rate of increase in
turbidity can be measured using a spectrophotometer
to quantify the endotoxin content of a sample. This
technique is known as the turbidimetric LAL assay. A
variation of this technique involves the addition of
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chromogenic substrates to LAL which undergoes a
colour change in the presence of endotoxin. The
chromogenic LAL assay has been the most commonly
used endotoxin detection method in previous human
studies and dialysis literature [2, 6]. However, in Japan,
the turbidimetric LAL assay is routinely used and is
covered by the Japanese national health insurance pro-
gram [7].
We recently demonstrated that a specific commercially
available kinetic turbidimetric Limulus Amoebocyte Lys-
ate (LAL) was an accurate and precise endotoxin detec-
tion assay in HD patients [8], although it is not known
whether LAL assays utilising chromogenic techniques
may have better performance since direct comparative
studies in ESKD patients have not been published. Using
the same study subjects [8], we carried out endotoxin
spike recovery experiments to directly compare the ac-
curacy and precision of a turbidimetric LAL with a
chromogenic LAL assay from the same manufacturer.
Methods
Participant selection
The whole study cohort consisted of seven clinically
stable patients undergoing outpatient HD (mean age 63)
at the Lister Renal Unit (Hertfordshire, UK) and seven
healthy controls (mean age 47) recruited from volunteers
and healthcare workers at the Lister Hospital (Hertford-
shire, UK). To minimise the possibility of high amounts
of native endotoxin present in plasma samples which
would interfere with endotoxin spike recovery experi-
ments, only subjects who were clinically well with no
evidence of sepsis were recruited to the study. Addition-
ally, HD patients were required to have a C-reactive pro-
tein (CRP) measurement of <5 mg/L within the last
month to be eligible for recruitment. Patients with a
venous catheter in-situ, liver dysfunction, congestive car-
diac failure and active gastrointestinal or inflammatory
diseases were not eligible for recruitment.
Blood collection
All phlebotomy equipment including blood collection
and storage tubes were checked for endotoxin contamin-
ation and interfering factors by random batch testing as
previously described [8, 9]. All apparatus had no detect-
able endotoxin (<0.005EU/ml). Blood samples were col-
lected aseptically into sterile Terumo Venoject II
heparinized tubes (Project KBF, Tokyo) and kept chilled
on ice. In HD patients, blood was sampled pre-dialysis
from the arteriovenous fistula. Blood samples were cen-
trifuged at 250 g for 10 min at 4 °C to obtain plasma
and stored in Eppendorf Biopur® safe-lock tubes and im-
mediately frozen and stored at −80 °C.
Plasma pre-treatment
Endotoxin spike recovery in uraemic plasma samples
spiked with high concentration endotoxin can be opti-
mised by diluting samples in Tween 80 compared to the
standard method of diluting in endotoxin-free water [8,
10]. Plasma samples were diluted 1:10 in 0.1 % Tween
80 (Merck Chemicals, Darmstadt, Germany) and heated
at 70 °C for 10 min to denature plasma proteins and
proteases which may interfere with endotoxin detection
by the LAL assay [11, 12]. Batches of 0.1 % Tween 80
were consistently found to have no detectable endotoxin
and were free of interfering factors (endotoxin spike re-
coveries ranged from 94 to 106 %). Samples were cooled
to room temperature (20–25 °C) prior to endotoxin
measurements.
Assessment of assay accuracy
Plasma samples from five HD patients and five healthy
controls were divided into aliquots and directly spiked
with five different concentrations of control standard
E.coli 055:B55 endotoxin (0 [unspiked sample], 0.05, 0.1,
0.5 and 2.5 EU/ml) and then diluted in 0.1 % Tween 80
and subjected to heat treatment as described above.
Each sample was tested for endotoxin content in sextu-
plicate using both the kinetic chromogenic and kinetic
turbidimetric LAL assay. Samples that contained bubbles
introducing artefact into optical density graphs were dis-
carded from the analysis. All samples had between four
to six repeated measurements. Percentage spike recovery
was calculated for each spiked plasma sample using the
formula:-
% spike recovery
¼ Measured endotoxin content in spiked sample
−Measured endotoxin content in unspiked sample
Amount of added endotoxin
 100%
The optimal spike recovery is 100 %, although a
spike recovery between 50 and 200 % is considered
valid according to industry guidance [13]. Assay accur-
acy was assessed by comparing difference in spike re-
covery between the chromogenic and turbidimetric
LAL assay using Wilcoxon signed rank test. Differ-
ences in baseline endotoxin content in unspiked sam-
ples between the chromogenic and turbidimetric assay
was compared using the Friedman test. Measured
endotoxin content was compared with expected endo-
toxin content in spiked samples using Bland-Altman
analysis [14] and linear regression analysis was used to
calculate slope and y-intercept of the line of best fit to
estimate magnitude of proportional and constant error
for both assays [15].
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Assessment of assay precision
Samples from two HD patients and two healthy controls
were pooled separately. Pooled HD and healthy control
plasma were spiked with two different concentrations of
control standard endotoxin (0.05 and 0.5 EU/ml), diluted
and heat treated as described earlier and subjected to
ten repeated assay measurements for endotoxin using
the kinetic chromogenic and kinetic turbidimetric LAL
assay to calculate a coefficient of variation (CV). The
CV is used to assess assay precision [16] but there is no
industry guidance on a maximum acceptable CV, al-
though most LAL manufacturers impose a CV <10–
20 % for results to be considered valid [16].
Endotoxin assays
Kinetic turbidimetric LAL assay: samples were assayed
using Endosafe KTA2 lysate (Charles River Laboratories,
France) on sterile 96-well microplates (manufacturer cer-
tified to <0.001EU/ml). Assays were carried out using
manufacturer supplied equipment including depyroge-
nated glass tube, pipettes and Eppendorf Endosafe pipette
tips (certified <0.005 EU/ml). Analysis of each microplate
consisted of duplicate wells containing endotoxin-free
water to act as a negative control. Plates were analysed
using a Biotek ELx808 absorbance microplate reader with
Endoscan-V software (version 4.0; Charles River Labora-
tories, France) and observed at 340 nm with an onset op-
tical density value set at 0.03 as per manufacturer’s
recommendations. Six-point standard curves were con-
structed using onset reaction times from standard dilu-
tions of control standard endotoxin (E.coli 055: B5)
ranging from 10 to 0.0025 EU/ml. All standard curves
constructed had a correlation coefficient of >0.98, as re-
quired for valid extrapolation of reaction times [13]. Due
to the ten-fold dilution used for plasma, the lower limit of
detection was 0.025 EU/ml.
Kinetic chromogenic LAL assay: samples were assayed
using Endochrome-K lysate (Charles River Laboratories,
France) with manufacturer supplied depyrogenated glass
tubes, pipettes and pipette tips as described above. Micro-
plates were analysed using FLUOstar Omega microplate
reader with MARS data analysis software (BMG Labtech,
Offenburg, Germany) and observed at 405 nm with an op-
tical density value of 0.1 as per manufacturer’s recommen-
dations. The same concentrations of control standard
endotoxin were used to construct standard curves as de-
scribed for the kinetic turbidimetric LAL assay.
Results
Comparison of assay accuracy between turbidimetric and
chromogenic LAL assay
This sub-study consisted of five HD patients and five
healthy controls. In unspiked plasma samples, the kin-
etic turbidimetric LAL assay detected endotoxemia in
four out of five HD patients whereas the kinetic chromo-
genic LAL assay detected endotoxemia in one out of five
HD patients (median endotoxin level 0.041 EU/ml [IQR
0.016–0.081]] vs. 0 EU/ml [IQR 0–0.017]; p < 0.001). In
healthy controls, only one subject had detectable endotox-
emia (0.027 EU/ml) using the turbidimetric assay. No
healthy subjects had detectable endotoxemia using the
chromogenic assay.
Spike recovery was within for the industry specified
50–200 % [13] range for all levels of spike using the
turbidimetric assay for both HD patients and healthy
controls. Spike recovery with the chromogenic assay
was significantly lower than the turbidimetric assay
for HD patients (53.8 % vs. 113.8 %; p < 0.001) and
healthy controls (34.0 % vs. 114.0 %; p < 0.001)
(Table 1). Notably, for the chromogenic assay spike re-
covery was frequently below the minimum required
spike recovery of 50 % suggesting persistent inhibition
of the chromogenic LAL assay by interfering factors
present in HD and healthy plasma despite dilution and
heat-treatment.
Comparison of assay error between turbidimetric and
chromogenic LAL assay
Comparison plots of measured versus expected endo-
toxin content in spiked samples were constructed (Fig. 1).
Correlation between measured and expected endotoxin
was higher for the turbidimetric assay compared to the
chromogenic assay for both HD patients (r = 0.962 vs.
0.939) and healthy subjects (r = 0.954 vs. 0.922). For HD
patients, estimates of proportional error and constant
error were lower for the turbidimetric assay (4.2 % and
0.016 EU/ml [−0.13 to 0.162]) compared to the chromo-
genic assay (32.2 % and −0.027 EU/ml [−0.094 to −
0.041]) (Table 2 and Fig. 1). In healthy subjects, overall
assay error was similarly lower in the turbidimetric assay
compared to the chromogenic assay (proportional error,
11.8 % vs. 59.0 %; constant error, 0.067 EU/ml [−0.011
to 0.145] vs. −0.011 EU/ml [−0.128 to 0.102]) (Table 2
and Fig. 1).
Bland-Altman analysis was used to assess assay bias
[14]. Bland-Altman plots for measured and expected
endotoxin spike recovery the turbidimetric and
chromogenic assay are shown in Fig. 2. Overall mean
bias for the chromogenic assay was −0.384 EU/ml
(95 % CI −0.219 to −0.549) and for the turbidimetric
assay mean bias was 0.011 EU/ml (95 % CI 0.079 to
−0.057). Sub-analysis of the HD cohort revealed mean
bias for the chromogenic assay was −0.291 EU/ml
(95 % CI −0.126 to −0.455) and significantly greater
than the turbidimetric assay (0.049 EU/ml [95 % CI
0.162 to −0.064]; p < 0.001). Similarly, in healthy sub-
jects there was greater bias with the chromogenic assay
compared with the turbidimetric assay (mean bias
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Table 1 Comparison of spike recovery of turbidimetric and chromogenic LAL assay
Concentration of endotoxin spike (EU/ml) 0 (unspiked sample) 0.05 0.1 0.5 2.5 Overall
Population
HD patients (n = 5) Chromogenic assay
Endotoxin content (EU/ml)
of sample
0 [IQR 0–0.017] 0.026 [IQR 0–0.049] 0.074 [IQR 0.033–0.1] 0.242 [IQR 0.198–0.331] 1.69 [IQR 1.492–1.859] -
Spike recovery (%) - 15.3 [IQR −7.3–97.6] 40.2 [IQR 32.8–100.4] 46.4 [IQR 39.6–63.8] 67.6 [IQR 59.7–73.7] 53.8 [IQR 34.0–78.9]
Turbidimetric assay
Endotoxin content (EU/ml) 0.041 [IQR 0.016–0.081] 0.109 [IQR 0.092–0.118] 0.176 [IQR 0.126–0.205] 0.525 [IQR 0.408–0.817] 2.715 [IQR 2.2–3.108] -
Spike recovery (%) - 125.3 [IQR 74.1–142.6] 129.9 [IQR 99.1–137] 96.7 [IQR 78.3–147.1] 108.6 [IQR 85.9–121.7] 113.8 [IQR 85.6–133.5]
P (for % spike recovery) 0.08 0.043* 0.043* 0.043* <0.001*
Healthy (n = 5) Chromogenic assay
Endotoxin content (EU/ml) 0 0 [IQR 0–0.03] 0.031[IQR 0–0.04] 0.258 [IQR 0.109–0.267] 0.944 [IQR 0.636–1.434] -
Spike recovery (%) - 0 [IQR 0–60.8] 31.5 [IQR 0–40.0] 51.5 [IQR 21.8–53.4] 37.7 [IQR 25.4–57.4] 34.0 [IQR 4.7–53.9]
Turbidimetric assay
Endotoxin content (EU/ml) 0 [IQR 0–0.013] 0.071 [IQR 0.061–0.12] 0.151 [IQR 0.141–0.174] 0.532 [IQR 0.503–0.616] 2.132 [IQR 2.108–2.46] -
Spike recovery (%) - 142.4 [IQR 95.1–212.5] 146.4 [IQR 127–173.4] 102.2 [IQR 99.9–123] 84.2 [IQR 82.6–101.3] 114.0 [IQR 98.3–145.4]
P (for % spike recovery) 0.043* 0.043* 0.043* 0.043* <0.001*
HD haemodialysis, EU/mL endotoxin units per millilitre
* denotes statistical significance P <0.05
W
ong
et
al.Journalof
Inflam
m
ation
 (2016) 13:24 
Page
4
of
9
−0.478 [95 % CI −0.776 to −0.180] vs. −0.021 EU/ml
[95 % CI −0.102 to 0.061]; p < 0.001).
Comparison of assay precision between turbidimetric and
chromogenic LAL assay
The CV calculated using the onset reaction time for
both cohorts was <10 % for both chromogenic and tur-
bidimetric assays. CV calculated using the actual endo-
toxin content of the sample was <10 % for the
turbidimetric LAL assay in pooled HD plasma samples
spiked with high concentration of endotoxin (0.5 EU/
ml), however in samples spiked with low concentration
of endotoxin (0.05 EU/ml), CV was higher at 24.1 % sug-
gesting imprecision of the turbidimetric assay at this low
endotoxin concentration in HD patients. With the
chromogenic assay, for samples spiked with high con-
centration of endotoxin (0.5 EU/ml), CV for HD patients
and healthy subjects was ranged from 25.8 to 26.5 %
suggesting high imprecision, CV for samples spiked with
low amounts of endotoxin endotoxin (0.05 EU/ml) could
not be defined because spike recovery was 0 % (Table 3).
Discussion
This is the first comparative study of two commonly
used LAL detection techniques in haemodialysis pa-
tients. Two kinetic LAL assays utilising chromogenic
and turbidimetric detection were compared directly in
this study. Kinetic assays have significant advantages
over older LAL techniques including the gel-clot and
end-point method. Kinetic assays are more sensitive,
able to quantify results over a wider range of endotoxin
concentrations and benefits from having an automated
process of analysis reducing the variation due to user
technique [5]. In a recent review of endotoxin studies
performed in dialysis patients [2], only one study utilised a
kinetic assay [17], the remaining studies employed either
the end-point technique [18, 19], the gel-point method
[20, 21] or were not specified [22–26]. Despite their wide-
spread availability and use, it is not known whether the
turbidimetric or the chromogenic assay has superior per-
formance in patients with end-stage kidney disease.
This study, using LAL reagents from the same manu-
facturer, has shown that the kinetic turbidimetric LAL
assay is a more accurate and precise endotoxin detection
tool compared to the chromogenic assay in HD patients
and is able to detect endotoxin over a wide range of dif-
ferent endotoxin concentrations (0.05 –2.5 EU/ml). Add-
itionally, this investigation showed that uraemic solutes
that accumulate in patients with kidney failure do not
appear to have any greater significant interference on
the LAL assay than non-uraemic plasma.
Endotoxin spike recovery with the chromogenic assay
was significantly inhibited by plasma from HD patients
and healthy controls despite attempts to remove inter-
fering factors from samples with dilution and heat treat-
ment. Spike recoveries with the chromogenic were
consistently below the minimum requirement of 50 %
for healthy controls and overall median spike recovery
Fig. 1 Comparison plots showing linear regression lines (hashed lines) for measured versus expected endotoxin content in spiked samples for HD
patients and healthy controls with the chromogenic and turbidimetric assay. Dotted lines represent 95 % confidence intervals for linear regression
lines. Each data point represents a mean of 4–6 measurements for one subject). Black reference line indicates perfect agreement between measured
and expected endotoxin content
Table 2 Comparison of assay error of turbidimetric and chromogenic LAL assay using linear regression analyses
Population Assay Slope Proportional error (%) Y-intercept (constant error) [EU/mL] Correlation coefficient
HD (n = 5) Turbidimetric 1.042 [0.927–1.157] 4.2 0.016 [−0.130–0.162] 0.962
Chromogenic 0.678 [0.625–0.731] 32.2 −0.027 [−0.094–0.041] 0.939
Healthy (n = 5) Turbidimetric 0.882 [0.821–0.943] 11.8 0.067 [−0.011–0.145] 0.954
Chromogenic 0.41 [0.320–0.500] 59 −0.011 [−0.128–0.102] 0.922
HD haemodialysis, EU/mL endotoxin units per millilitre
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was borderline acceptable at 53.8 % for the HD cohort.
In comparison, median spike recovery for the turbidi-
metric assay was 113.8 %, well within the industry speci-
fied 50–200 % requirement [13]. The magnitude of assay
error and bias was also greater for the chromogenic
assay for both HD and healthy control subjects. Assay
precision in this study was assessed using the coefficient
of variation calculated from both the onset reaction time
and the endotoxin content of the sample. There is a lack
of industry guidance on which variable should be used
to calculate the CV, depending on the manufacturer either
the onset reaction time or the endotoxin read-out meas-
urement can be used [16]. It has been suggested that CV
calculated using the endotoxin content of samples is a
more rigorous measure of assay precision [16]. Using the
onset reaction time, CV was <10 % for both the turbidi-
metric and chromogenic LAL assay. However, CV calcu-
lated using the endotoxin content of the sample showed
that the turbidimetric assay was more precise than the
chromogenic assay. But in low levels of endotoxemia
(≤0.05 EU/ml), assay imprecision was higher (CV −9.3 to
24.1 %) and care should be taken at interpreting samples
containing low concentration of endotoxins.
Turbidimetric assays have the advantage of being more
economical and a historical comparative study in non-
uraemic plasma favoured the turbidimetric over the
chromogenic assay because of the interfering effect of
chromogenic substrates on the kinetics of the LAL
reaction [27]. For end-point LAL assays, the chromo-
genic assay may suffer from interference as plasma and
serum samples can absorb light at the measured 405 nm
wavelength, potentially interfering with the results [28].
The LAL assay has been extensively used for the de-
tection of endotoxin in pharmaceutical products, how-
ever its use in blood has been a matter of intense debate
[29, 30]. Currently the LAL assay is not licensed by the
Food and Drug Administration for ‘detecting endotoxe-
mia in man’. This decision was heavily influenced by
studies conducted by Stumacher [31] in 1973 and Elin in
1975 [32] demonstrating lack of concordance between
endotoxemia and bacteraemia [29]. However, others
have debated the validity of trials which measured the
correlation of the LAL assay with positive culture bac-
teraemia as a ‘gold-standard’ [29], which is well known
to have a low sensitivity for identifying patients with
sepsis [33].
Due to current limitations with the LAL assay, a num-
ber of different novel detection assays have evolved over
the last few decades including the recombinant factor C
assay (rFC), the Endotoxin Scattering Photometry (ESP)
assay and the Endotoxin Activity Assay (EAA) – a bio-
assay based on neutrophil activation by complement
opsonised immune complexes of LPS [34]. No studies
on the use of the rFC assay in human blood have been
published to date. The ESP assay is a relatively novel de-
tection system with its efficacy examined in a small
Fig. 2 Bland-Altman analysis of measured versus expected spike recovery for the turbidimetric and chromogenic LAL assay in HD patients and
healthy subjects (dotted lines represents 95 % limits of agreement)
Table 3 Coefficient of variation of turbidimetric and chromogenic assay in pooled uremic and non-uremic plasma
Concentration of endotoxin spike (EU/mL) CV - onset reaction time (%) CV - EU/ml (%)
0.05 0.5 0.05 0.5
Population Assay
HD (n = 2) Turbidimetric 4.6 2.5 24.1 8.9
Chromogenic 2.4 3.8 Undefined 25.8
Healthy (n = 2) Turbidimetric 2.8 1.3 9.3 4.5
Chromogenic 5.4 4.6 Undefined 26.5
In samples where spike recovery was 0 %, CV was undefined. CV coefficient of variation, EU/mL endotoxin units per millilitre
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number of trials [35–37]. The EAA is an FDA-approved
blood endotoxin detection assay, however the EAA pro-
vides a read-out of a patient’s neutrophil oxidative
chemi-luminescent response to LPS-antibody complexes
rather than the direct endotoxin content present in the
sample [34]. A recent investigation found a poor dose–
response between blood spiked with control standard
endotoxin and EAA activity [7]. Comparative studies be-
tween the optimum LAL assay and these novel detection
assays would be useful.
The strengths of our study includes our meticulous at-
tention to pre-analytical factors such as careful selection
of blood sampling accessories by testing apparatus for
contamination and interfering factors. No blood samples
were obtained from tunnelled dialysis catheters to re-
duce the risk of contamination by bacterial biofilms [38].
Blood sampling and processing was performed rapidly to
reduce the risk of endotoxin inactivation in untreated
plasma [11]. The United States Pharmacopoeia states
that in kinetic LAL testing, test samples need to be
verified to be free of assay interfering factors by
obtaining a spike recovery between 50 and 200 % from
a positive product control (PPC) for an endotoxin
measurement from a sample to be considered valid
[13]. The PPC is a duplicate of the sample spiked with
LPS at a concentration that lies near the mid-point of
the standard curve after dilution and heat treatment.
In this study, plasma samples were spiked with several
different quantities of LPS prior to dilution and heat
treatment which enables us to examine the ability of
the assays to retrieve LPS from plasma containing wide
range of different concentrations of endotoxin. Spiking
samples before dilution and heat treatment to measure
spike recovery also more closely resemble the process
experienced by naturally occurring endotoxins present
in the sample.
The limitations of this study include the relatively
small number of participants and the use of control
standard endotoxin derived to assess spike recovery.
Standard endotoxins are derived from E.coli and are
usually stabilised in preservatives such as lactulose and
polyethylene glycol which may behave differently in vivo
compared to naturally occurring endotoxin. However,
natural endotoxins are difficult to standardise and many
other published studies also use control standard endo-
toxin to assess recovery or immune response [10, 11, 27,
39–41]. The incubation times for samples spiked with
endotoxin were not controlled due to the large number
of samples that were processed, although laboratory ana-
lyses of spiked samples was carried out as soon as pos-
sible. It is unclear whether different incubation times
can affect spike recovery. However since the same spik-
ing procedure was used throughout the whole study by
the same operator, incubation times would have been
broadly similar between samples. We did not investigate
whether the endotoxin measured in some of the baseline
samples may have been due to (1→ 3) β-D glucan inter-
ference, which is well known to have the ability to acti-
vate the LAL assay via the factor G pathway [42], since
the LAL assay used in this study was not modified to be
insensitive to factor G activation. However, LAL is nearly
1000-times more sensitive to endotoxins than (1→ 3) β-
D glucan [43] and contamination with (1→ 3) β-D glu-
can can usually be recognised by significant enhance-
ment of spike recoveries [42], which was not seen in this
study. Only one form of blood pre-treatment method
(1:10 dilution and heat treatment at 70 °C for 15 min)
was used in this study to remove interfering factors
therefore the findings of this study may not be applicable
if other blood pre-treatment methods were used. We did
not explore different dilution or heating conditions,
however the plasma pre-treatment conditions selected
for this study were based on an extensive review by Hur-
ley [11] and it is likely that the pre-treatment process for
removal of interfering factors was sufficient since the
overall spike recovery for the turbidimetric assay was
>100 %. Our findings could also be criticised in that,
since we compared chromogenic and turbidimetric as-
says using LAL reagent from one manufacturer only,
our conclusions may not apply with use of reagents
from other manufacturers. However the materials and
methods described by the manufacturer are FDA ap-
proved for the testing of endotoxin prior to medical
product release. As such, each batch is assessed and
certified by the company and should be directly com-
parable with similar products from other manufac-
turers. Nevertheless, we suggest that assessment with
reagents from alternative manufacturers is required
before more general conclusions can be drawn.
Conclusions
In summary, the association of endotoxemia with inflam-
mation in dialysis patients needs to be confirmed with an
accurate endotoxin detection assay to increase under-
standing of the potential harmful effects of chronic
endotoxemia in this population and to develop endotoxin-
lowering interventions. The study findings suggest that
the kinetic turbidimetric LAL assay is a more accurate
and precise assay compared to the chromogenic LAL
assay, though these findings should be verified using LAL
reagents from other sources.
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